Reinnervate, the life sciences company driving the adoption of routine 3D cell culture, is delighted to announce the appointments of Richard Rowling as Commercial Director and Barry Lynch as Marketing Manager to lead the sales and marketing operations supporting alvetex, the Company’s breakthrough 3D cell culture technology. Dr Györgyi Talas also joins reinnervate as Product Development Manager.
The three new appointments represent an important milestone for reinnervate as it continues to expand its commercial and product development teams following the initial launch of alvetex in a 12-well plate format late last year and in preparation for further product launches scheduled throughout 2011.
As Commercial Director, Richard Rowling will have overall responsibility for the sales and marketing strategy and brings to the position over 20 years of experience marketing life science products globally. Since 2007, Richard worked as Sales and Marketing Director for Lab 901 Ltd where he was responsible for the commercialisation of its new automated electrophoresis platform and for the development of a full marketing and sales plan for the company’s RNA and protein research products. Prior to Lab 901, Richard was the Director, European Marketing & Telesales at Invitrogen Ltd, a leading global life science supplier.
Barry Lynch’s career includes over 12 years of international sales and marketing experience. Most recently he worked as the International Business Manager at Oxford Immunotec Ltd where he led strategic and tactical market development activities including establishing a highly trained and effective network of distributors for the company’s tuberculosis infection diagnostic. Prior to that Barry spent over ten years in regional marketing and product management roles at Invitrogen and latterly Applied Biosystems (both now part of Life Technologies).
Dr Györgyi Talas joins reinnervate from Angel Biotechnology Plc where she was responsible for all process and product development activities in the area of cell culture and successfully facilitated their transition to GMP. She has over 20 years’ academic and industrial experience within the fields of tissue engineering and cell therapy. Györgyi also spent eight years as Senior Scientist and Project Leader at Intercytex Plc developing cell therapy products for woundcare and aesthetic medicine markets prior to the company’s sale in 2009.
Ashley Cooper, reinnervate’s CEO, said: “We are very pleased to have attracted commercial and product development professionals with the quality and experience of Richard, Barry and Györgyi. Reinnervate is entering a very exciting period following the launch of our first alvetex product late last year. We had a tremendous reception to this launch and there appears to be great demand for alvetex as researchers are increasingly moving towards 3D cell culture. With these excellent new appointments and a pipeline of innovative alvetex products in development, reinnervate will now drive forward its commercial and product development strategies.”
Richard Rowling said: “Reinnervate has developed a truly unique technology in alvetex, which has the potential to revolutionise 3D cell culture and provide better in vitro testing models. I am excited to be joining reinnervate at this crucial stage in its development and applying my experience to support its commercial ambitions.”
Reinnervate’s core technology is alvetex, a scaffold that enables routine 3D cell culture in the laboratory. Alvetex provides a nanoscale environment that supports genuine homogeneous 3D cell growth. Cells grown using alvetex form complex 3D tissue cultures, which more closely mimic normal in-vivo cell growth and the formation of tissues in the body. The use of alvetex-derived 3D cell cultures can provide researchers with greater insight into how cells behave in the body in response to external factors (such as drug candidates) than is currently possible with existing 2D or other emerging 3D cell culture technologies.
Reinnervate has generated significant data, which have been published extensively in peer-reviewed publications, exemplifying the use of alvetex in a large number of cell types and applications. Alvetex is being developed for commercialisation in a range of formats and is due to be launched in 2010.
Reinnervate is also using its cell biology expertise to generate a library of synthetic small molecules that mediate stem cell differentiation in vitro. The first of these small molecules, ec23, is commercially available and offers the potential for robust and reproducible differentiation of neural cell types.